Israele - inglese - Ministry of Health

j-c health care ltd - paliperidone - tablets extended release - paliperidone 3 mg - paliperidone - paliperidone - invega is indicated for :-treatment of schizophrenia in adults and adolescents (12-17 years).-treatment of schizoaffective disorder in adults.

Israele - inglese - Ministry of Health

j-c health care ltd - paliperidone - tablets extended release - paliperidone 6 mg - paliperidone - paliperidone - invega is indicated for :-treatment of schizophrenia in adults and adolescents (12-17 years).-treatment of schizoaffective disorder in adults.

Israele - inglese - Ministry of Health

j-c health care ltd - paliperidone - tablets extended release - paliperidone 9 mg - paliperidone - paliperidone - invega is indicated for :-treatment of schizophrenia in adults and adolescents (12-17 years).-treatment of schizoaffective disorder in adults.

Australia - inglese - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - paliperidone palmitate, quantity: 156 mg (equivalent: paliperidone, qty 100 mg) - injection - excipient ingredients: dibasic sodium phosphate; water for injections; macrogol 4000; monobasic sodium phosphate monohydrate; polysorbate 20; citric acid monohydrate; sodium hydroxide - invega sustenna is indicated for the acute and maintenance treatment of schizophrenia in adults.

Australia - inglese - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - paliperidone palmitate, quantity: 117 mg (equivalent: paliperidone, qty 75 mg) - injection - excipient ingredients: sodium hydroxide; polysorbate 20; macrogol 4000; water for injections; dibasic sodium phosphate; monobasic sodium phosphate monohydrate; citric acid monohydrate - invega sustenna is indicated for the acute and maintenance treatment of schizophrenia in adults.

Australia - inglese - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - paliperidone palmitate, quantity: 39 mg (equivalent: paliperidone, qty 25 mg) - injection - excipient ingredients: dibasic sodium phosphate; sodium hydroxide; monobasic sodium phosphate monohydrate; citric acid monohydrate; polysorbate 20; water for injections; macrogol 4000 - invega sustenna is indicated for the acute and maintenance treatment of schizophrenia in adults.

Australia - inglese - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - paliperidone palmitate, quantity: 234 mg (equivalent: paliperidone, qty 150 mg) - injection - excipient ingredients: monobasic sodium phosphate monohydrate; citric acid monohydrate; water for injections; polysorbate 20; macrogol 4000; dibasic sodium phosphate; sodium hydroxide - invega sustenna is indicated for the acute and maintenance treatment of schizophrenia in adults.

Australia - inglese - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - paliperidone palmitate, quantity: 78 mg (equivalent: paliperidone, qty 50 mg) - injection - excipient ingredients: macrogol 4000; polysorbate 20; water for injections; citric acid monohydrate; dibasic sodium phosphate; sodium hydroxide; monobasic sodium phosphate monohydrate - invega sustenna is indicated for the acute and maintenance treatment of schizophrenia in adults.

Australia - inglese - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - paliperidone, quantity: 9 mg - tablet, modified release - excipient ingredients: sodium chloride; iron oxide red; purified water; hyetellose; macrogol 3350; carnauba wax; butylated hydroxytoluene; polyethylene oxide; povidone; stearic acid; isopropyl alcohol; propylene glycol; iron oxide black; hypromellose; titanium dioxide; macrogol 400; cellulose acetate - invega is indicated for the treatment of schizophrenia, including acute treatment and recurrence prevention. invega is indicated for the treatment of acute exacerbations of schizoaffective disorder as monotherapy and in combination with antidepressants and/or mood stabilizers (lithium and valproate).

Australia - inglese - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - paliperidone, quantity: 6 mg - tablet, modified release - excipient ingredients: butylated hydroxytoluene; sodium chloride; povidone; stearic acid; polyethylene oxide; iron oxide red; hyetellose; macrogol 3350; macrogol 400; carnauba wax; isopropyl alcohol; propylene glycol; cellulose acetate; titanium dioxide; hypromellose; purified water; iron oxide black; iron oxide yellow - invega is indicated for the treatment of schizophrenia, including acute treatment and recurrence prevention. invega is indicated for the treatment of acute exacerbations of schizoaffective disorder as monotherapy and in combination with antidepressants and/or mood stabilizers (lithium and valproate).